

78

Change(s) applied *Please amend Paragraph No. 195 as follows:*

to document,

/A.G./ FIG. 9B depicts the effect of plasma lipase, a marker on pancreatic function, by an

11/14/2011 exemplary compound (SEQ ID NO:137) of the invention.

81

Please amend Paragraph No. 196 as follows:

FIG. 11A depicts the gastric mucosal protection gastroprotective effect of amylin.

82

Please amend Paragraph No. 197 as follows:

FIG. 11B depicts the gastric mucosal injury score gastroprotective effect of amylin.

61

Please amend the Table in the originally-filed specification at Page 62 as follows:

Table 2 X. EC₅₀ values (nM) for polypeptides

Compound	Amylin	Calcitonin	CGRP
1	0.028	0.029	2.342
2	0.047	0.052	33.988
3	0.023	0.020	0.490
4	0.035	0.019	8.500
5	0.022	0.018	2.600
6	0.030	nt	nt
7	0.057	nt	7.540
8	8.070	0.478	175.665
9	0.043	0.014	1.600

nt denotes not tested

Amendments to the Specification:

The following amendments to the specification are made with reference to the published US application (i.e., US Publication No. 2008/0274952) unless otherwise noted.

Please amend the Title of the Invention as follows:

Amylin Family Peptides and Methods for Making and Using Them for Treatment

Change(s) applied *Please amend Paragraph No. ⁷³~~188~~ as follows:*

to document,

/A.G./

11/14/2011

Figures 6A-6C FIG. 6A-6B depict the effect on triglycerides after 1 week (Fig. 6A), 2 weeks (Fig. 6B), and 3 weeks (Fig. 6C) over time by an exemplary compound (SEQ ID NO:137) of the invention.

Please amend Paragraph No. ⁷⁴~~189~~ as follows:

FIGS. 7A-7E depict the dose effect on triglycerides at baseline (Fig. 7A) and after 2 weeks (Fig. 7B), 4 weeks (Fig. 7C), 6 weeks (Fig. 7D), and 8 weeks (Fig. 7E) over time by an exemplary compound (SEQ ID NO:137) of the invention.

Please amend Paragraph No. ⁷⁵~~190~~ as follows:

FIG. 8A depicts the effect on ghrelin by amylin following the administration of a pentagastrin injection.

Please amend Paragraph No. ⁷⁶~~191~~ as follows:

FIGS. 8B-8C depict the comparative effect on ghrelin by saline and 30 µg/kg of amylin without a pentagastrin injection (Fig. 8B) and following a pentagastrin injection (Fig. 8C).

Please amend Paragraph No. ⁷⁷~~192~~ as follows:

FIG. 9A depicts the effect of plasma amylase, a marker on pancreatic function, by an exemplary compound (SEQ ID NO:137) of the invention.